Perspectives in Antiinfective Therapy PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Perspectives in Antiinfective Therapy PDF full book. Access full book title Perspectives in Antiinfective Therapy by G.G. Jackson. Download full books in PDF and EPUB format.
Author: G.G. Jackson
Publisher: Springer-Verlag
ISBN: 3322860647
Category : Medical
Languages : de
Pages : 292
Get Book Here
Book Description
Author: G.G. Jackson
Publisher: Springer-Verlag
ISBN: 3322860647
Category : Medical
Languages : de
Pages : 292
Get Book Here
Book Description
Author: G. G. Jackson
Publisher:
ISBN:
Category :
Languages : en
Pages : 299
Get Book Here
Book Description
Author: K. Tamreihao
Publisher: Bentham Science Publishers
ISBN: 9811432724
Category : Medical
Languages : en
Pages : 278
Get Book Here
Book Description
The volume is a comprehensive documentation on major infectious diseases from tropical countries which pose a serious threat to global healthcare programs. These include diseases such as tuberculosis, AIDS, leishmaniasis (kala-azar), elephantiasis, malaria, leprosy, various fungal disorders and emergent viral diseases. Due to the widespread use of antibiotics, there is an emergence of drug-resistant pathogens in many regions. Hence, there is a need to search for novel, cost-effective bioactive compounds that demonstrate high efficacy and low toxicity in human cells from unexplored ecosystems to combat emerging drug-resistant pathogens. Chapters of this volume focus on the pathogenesis and etiology of each of the mentioned diseases, updated WHO reports wherever applicable, conventional drugs and their pharmacokinetics as well as new approaches to develop anti-infective agents. The authors also present a detailed report on ‘superbugs’ (multi-drug resistant pathogens) and new measures being taken up to eradicate them. Information about new antimicrobials (bioactive peptides and silk protein sericin) and the approaches taken by scientists and healthcare professionals for successful targeting of these molecules for human medicine. This volume is essential for general readers, healthcare professionals, researchers, and academicians actively involved in research on infectious diseases and anti-infective therapeutic drugs. [Series Introduction] Frontiers in Anti-Infective Agents is a book series that focuses on current and new antibiotics and vaccines. The series highlights the challenges faced by healthcare workers around the globe when facing epidemics caused by life-threatening pathogens along with the measures being taken to combat these challenges. The series is essential reading for all involved in infectious disease research including microbiologists, medical professionals, epidemiologists, and life science researchers.
Author: George Gee Jackson
Publisher: Springer Verlag
ISBN: 9783540509646
Category : Medical
Languages : en
Pages : 478
Get Book Here
Book Description
Author: George G. Jackson
Publisher: Springer
ISBN: 9783642466670
Category : Medical
Languages : en
Pages : 478
Get Book Here
Book Description
Pharmaceutical research has a long-standing tradition at Bayer since the establish ment of a Pharmaceutical Department 25 years after the foundation of the Farben fabriken of Friedrich Bayer & Co. in the city of Elberfeld, Germany. In 1888, one of the first antipyretic drugs, phenacetin, was synthesized. A milestone was marked by the discovery and launch of Aspirin TM in 1899, the most widely used and appreciated drug since then. The success of Bayer 205 (GermaninTM) in the treatment of sleeping sickness led not only to the worldwide recognition of Bayer as a pharmaceutical company but also to intense research into antiinfective therapy. The antimalarial drugs Atebrin TM, Plasmochin TM and Resochin TM were the first of a whole series of significant contribu tions and even breakthroughs in the therapy of infections. The advances and the success of antibacterial therapy were heralded by the discovery of the antibacterial activity of the sulfonamides by Domagk, Klarer and Mietsch. The first drug of this class of compounds, ProntosilTM, opened the new era of therapeutic control of bacterial infections. In 1939, Domagk received the Nobel Prize for Medicine for this breakthrough. A further breakthrough in the chemotherapy of the scourge of tuber culosis was achieved in 1946 by Domagk and his colleagues Behnisch, Mietzsch and Schmidt with the development of Conteben TM, followed shortly afterwards by the discovery of isoniazid (Neoteben TM) by Domagk, Offe and Siefken.
Author: W.-D. Busse
Publisher: Springer Science & Business Media
ISBN: 3642608035
Category : Medical
Languages : en
Pages : 90
Get Book Here
Book Description
At a symposium in Wuppertal held on 26 September 1995, Dr. Karl-Georg Metzger was honored, on the occasion of his retirement, for his scientific contributions and involvement in antibacterial drug research and develop ment within Bayer AG. In 1963 Dr. Metzger was the first "molecular micro biologist" to join Bayer in the field of antibacterial research. Karl-Georg Metzger studied physics and biology at the University of Mainz from 1950 to 1953 and continued his scientific education, with a grant from the Deutsche Forschungsgemeinschaft, in Frankfurt on Main (1953-1956). From 1956 to 1958, under Professor Kaplan, he worked on his DNA following treatment of PhD, studying on "Energy conduction along bacteria with UV light and X-rays and the formation of mutations". He was awarded his PhD in 1959. From 1958 to 1963 he was research assistant in ra diobiology development at the Institute of Genetics in Cologne. During the following years he became fascinated by the emerging fields of molecular biology and gene technology. He worked together with the molecular gen eticists W. Harms and M. Delbriick, who built up one of the most renowned institutes in the world, in Cologne. ''An incredibly interesting time:' Dr. Metzger remembers, in which he got to know a whole series of Nobel prize winners from Niels Bohr to Watson and Crick and Joshua Lederberg, the first to recombine genotypes of bacteria.
Author: Anton Ficai
Publisher: Elsevier
ISBN: 0323461514
Category : Science
Languages : en
Pages : 724
Get Book Here
Book Description
Nanostructures for Antimicrobial Therapy discusses the pros and cons of the use of nanostructured materials in the prevention and eradication of infections, highlighting the efficient microbicidal effect of nanoparticles against antibiotic-resistant pathogens and biofilms. Conventional antibiotics are becoming ineffective towards microorganisms due to their widespread and often inappropriate use. As a result, the development of antibiotic resistance in microorganisms is increasingly being reported. New approaches are needed to confront the rising issues related to infectious diseases. The merging of biomaterials, such as chitosan, carrageenan, gelatin, poly (lactic-co-glycolic acid) with nanotechnology provides a promising platform for antimicrobial therapy as it provides a controlled way to target cells and induce the desired response without the adverse effects common to many traditional treatments. Nanoparticles represent one of the most promising therapeutic treatments to the problem caused by infectious micro-organisms resistant to traditional therapies. This volume discusses this promise in detail, and also discusses what challenges the greater use of nanoparticles might pose to medical professionals. The unique physiochemical properties of nanoparticles, combined with their growth inhibitory capacity against microbes has led to the upsurge in the research on nanoparticles as antimicrobials. The importance of bactericidal nanobiomaterials study will likely increase as development of resistant strains of bacteria against most potent antibiotics continues. - Shows how nanoantibiotics can be used to more effectively treat disease - Discusses the advantages and issues of a variety of different nanoantibiotics, enabling medics to select which best meets their needs - Provides a cogent summary of recent developments in this field, allowing readers to quickly familiarize themselves with this topic area
Author:
Publisher:
ISBN:
Category : Anti-infective therapeutics
Languages : en
Pages : 0
Get Book Here
Book Description
Author: George Gee Jackson
Publisher:
ISBN:
Category :
Languages : de
Pages : 478
Get Book Here
Book Description
Author: Scott H. Podolsky
Publisher: JHU Press
ISBN: 0801889286
Category : Medical
Languages : en
Pages : 448
Get Book Here
Book Description
“Uses [pneumonia] as a vehicle for examining the evolution of therapeutics in America between the ‘Golden Age of Microbiology’ and the ‘Age of Antibiotics.’”—Isis Focusing largely on the treatment of pneumonia in first half of the century with type-specific serotherapy, clinician-historian Scott H. Podolsky provides insight into the rise and clinical evaluation of therapeutic “specifics,” the contested domains of private practice and public health, and—as the treatment of pneumonia made the transition from serotherapy to chemotherapy and antibiotics—the tempo and mode of therapeutic change itself. Type-specific serotherapy, founded on the tenets of applied immunology, justified by controlled clinical trials, and grounded in a novel public ethos, was deemed revolutionary when it emerged to replace supportive therapeutics. With the advent of the even more revolutionary sulfa drugs and antibiotics, pneumonia ceased to be a public health concern and became instead an illness treated in individual patients by individual physicians. Podolsky describes the new therapeutics and the scientists and practitioners who developed and debated them. He finds that, rather than representing a barren era in anticipation of some unknown transformation to come, the first decades of the twentieth-century shaped the use of, and reliance upon, the therapeutic specific throughout the century and beyond. This intriguing study will interest historians of medicine and science, policymakers, and clinicians alike. “Podolsky’s scholarship is awesome, and his grasp of the philosophical and sociologic context of the issues considered make this an important work.” —New England Journal of Medicine “This thoroughly documented, carefully written book is a landmark analysis . . . It should be read by everyone who is involved in research and therapeutic development.” —JAMA
